公开(公告)号：US20150238569A1

公开(公告)日：2015-08-27

申请号：US14429856

申请日：2013-09-23

申请人： OHIO STATE INNOVATION FOUNDATION

发明人： Carlo M. Croce ,  Giulia Romano

IPC分类号： A61K38/19 ,  A61K45/06 ,  C12Q1/68 ,  A61K31/713

CPC分类号： C12N15/1135 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/1761 ,  A61K38/19 ,  A61K45/06 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/16 ,  C12Q2600/178 ,  G01N33/574 ,  G01N33/6863 ,  G01N2800/52 ,  A61K2300/00

摘要： Methods and compositions for inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof, comprising administering an effective amount of an anti-miR-494 nucleic acid construct sufficient to target one or more tumor suppressor genes (TSGs) are described. Activation of the ERK1/2 pathway is a major determinant of diverse cellular processes and cancer development and is responsible for the transcription of several important miRNAs. Described herein is a link between the ERK1/2 pathway and BIM expression through miR-494. This ERK1/2 pathway regulates apoptosis and cell proliferation through miR-494 and mechanisms responsible for TRAIL resistance. Materials and methods related to the study and treatment of cancer are described.

摘要翻译： 描述了在有需要的受试者中体外和体内抑制致瘤性的方法和组合物，包括给予有效量的足以靶向一种或多种肿瘤抑制基因（TSG）的抗miR-494核酸构建体。 ERK1 / 2途径的激活是多种细胞过程和癌症发展的主要决定因素，并且是几种重要miRNA的转录的主要因素。 本文描述了通过miR-494的ERK1 / 2途径和BIM表达之间的联系。 这种ERK1 / 2途径通过miR-494和负责TRAIL抗性的机制调节细胞凋亡和细胞增殖。 描述了与癌症研究和治疗相关的材料和方法。

公开(公告)号：US20160319285A1

公开(公告)日：2016-11-03

申请号：US15213551

申请日：2016-07-19

申请人： Ohio State Innovation Foundation

发明人： Carlo M. Croce ,  Giulia Romano

IPC分类号： C12N15/113 ,  G01N33/574 ,  G01N33/68 ,  C12Q1/68

CPC分类号： C12N15/1135 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/1761 ,  A61K38/19 ,  A61K45/06 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/16 ,  C12Q2600/178 ,  G01N33/574 ,  G01N33/6863 ,  G01N2800/52 ,  A61K2300/00

摘要： Methods and compositions for inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof, comprising administering an effective amount of an anti-miR-494 nucleic acid construct sufficient to target one or more tumor suppressor genes (TSGs) are described. Activation of the ERK1/2 pathway is a major determinant of diverse cellular processes and cancer development and is responsible for the transcription of several important miRNAs. Described herein is a link between the ERK1/2 pathway and BIM expression through miR-494. This ERK1/2 pathway regulates apoptosis and cell proliferation through miR-494 and mechanisms responsible for TRAIL resistance. Materials and methods related to the study and treatment of cancer are described.

公开(公告)号：US09427460B2

公开(公告)日：2016-08-30

申请号：US14429856

申请日：2013-09-23

申请人： Ohio State Innovation Foundation

发明人： Carlo M. Croce ,  Giulia Romano

IPC分类号： C07H21/02 ,  C07H21/04 ,  C12N15/85 ,  A61K38/19 ,  A61K38/17 ,  C12Q1/68 ,  C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  A61K31/7105 ,  G01N33/574 ,  G01N33/68

CPC分类号： C12N15/1135 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/1761 ,  A61K38/19 ,  A61K45/06 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/16 ,  C12Q2600/178 ,  G01N33/574 ,  G01N33/6863 ,  G01N2800/52 ,  A61K2300/00

摘要： Methods and compositions for inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof, comprising administering an effective amount of an anti-miR-494 nucleic acid construct sufficient to target one or more tumor suppressor genes (TSGs) are described. Activation of the ERK1/2 pathway is a major determinant of diverse cellular processes and cancer development and is responsible for the transcription of several important miRNAs. Described herein is a link between the ERK1/2 pathway and BIM expression through miR-494. This ERK1/2 pathway regulates apoptosis and cell proliferation through miR-494 and mechanisms responsible for TRAIL resistance. Materials and methods related to the study and treatment of cancer are described.

摘要翻译： 描述了在有需要的受试者中体外和体内抑制致瘤性的方法和组合物，包括给予有效量的足以靶向一种或多种肿瘤抑制基因（TSG）的抗miR-494核酸构建体。 ERK1 / 2途径的激活是多种细胞过程和癌症发展的主要决定因素，并且是几种重要miRNA的转录的主要因素。 本文描述了通过miR-494的ERK1 / 2途径和BIM表达之间的联系。 这种ERK1 / 2途径通过miR-494和负责TRAIL抗性的机制调节细胞凋亡和细胞增殖。 描述了与癌症研究和治疗相关的材料和方法。